Hypoplastic acute myeloid leukaemia with 7 years of complete remission by low-dose cytosine arabinoside therapy alone. 1995

H Mori, and K Fuchigami, and K Nagai, and T Kohno, and T Maeda, and H Nakamura, and K Kuriyama, and K Izumikawa, and M Tomonaga

UI MeSH Term Description Entries
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

H Mori, and K Fuchigami, and K Nagai, and T Kohno, and T Maeda, and H Nakamura, and K Kuriyama, and K Izumikawa, and M Tomonaga
June 1984, British journal of haematology,
H Mori, and K Fuchigami, and K Nagai, and T Kohno, and T Maeda, and H Nakamura, and K Kuriyama, and K Izumikawa, and M Tomonaga
January 1995, [Rinsho ketsueki] The Japanese journal of clinical hematology,
H Mori, and K Fuchigami, and K Nagai, and T Kohno, and T Maeda, and H Nakamura, and K Kuriyama, and K Izumikawa, and M Tomonaga
June 1988, Sangre,
H Mori, and K Fuchigami, and K Nagai, and T Kohno, and T Maeda, and H Nakamura, and K Kuriyama, and K Izumikawa, and M Tomonaga
September 1971, The New Zealand medical journal,
H Mori, and K Fuchigami, and K Nagai, and T Kohno, and T Maeda, and H Nakamura, and K Kuriyama, and K Izumikawa, and M Tomonaga
March 1997, Blood reviews,
H Mori, and K Fuchigami, and K Nagai, and T Kohno, and T Maeda, and H Nakamura, and K Kuriyama, and K Izumikawa, and M Tomonaga
August 1984, Ugeskrift for laeger,
H Mori, and K Fuchigami, and K Nagai, and T Kohno, and T Maeda, and H Nakamura, and K Kuriyama, and K Izumikawa, and M Tomonaga
June 1986, [Rinsho ketsueki] The Japanese journal of clinical hematology,
H Mori, and K Fuchigami, and K Nagai, and T Kohno, and T Maeda, and H Nakamura, and K Kuriyama, and K Izumikawa, and M Tomonaga
June 1987, Japanese journal of clinical oncology,
H Mori, and K Fuchigami, and K Nagai, and T Kohno, and T Maeda, and H Nakamura, and K Kuriyama, and K Izumikawa, and M Tomonaga
January 1987, European journal of haematology,
H Mori, and K Fuchigami, and K Nagai, and T Kohno, and T Maeda, and H Nakamura, and K Kuriyama, and K Izumikawa, and M Tomonaga
July 1985, British journal of haematology,
Copied contents to your clipboard!